Recent Updates
Recently added Catalysts
PTGX Positive Sentiment

US FDA Approval of MIMRYLO™(rusfertide) for Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)

Key Takeaway: Protagonist has received FDA approval for MIMRYLO™ (rusfertide), a treatment for erythrocytosis in adults with Polycythemia Vera (PV). This approval marks a significant milestone in addressing the medical needs of PV patients. The company emphasizes its commitment to diversity and inclusion within its workforce, which it views as essential for innovation and success.

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA approval signifies a major advancement in treatment options.
  • MIMRYLO™ addresses a critical need for patients with Polycythemia Vera.
  • Protagonist is committed to diversity and inclusion in its workforce.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+39%
120-day peak, hindsight
Typical move
3.6%
average across 3 past catalysts
Lead asset
PTG-300
Phase 2 · β-thalassemia

Full Press Release Details

Protagonist: Inclusion by the Numbers

Spotlight: Carena Spivey, Head of HR

Carena, equality, inclusion, and workplace diversity have long been in focus at Protagonist, as expressed through various programs and initiatives. Can you tell us about your approach?

We view our diverse and welcoming corporate culture as being critical to our long-term success – It’s essential to the way we innovate. And we regularly track and report our progress, because we believe that what doesn’t get measured doesn’t get done. Today: - 65% of employees are members of underrepresented ethnic communities - 51% are women - nearly 50% of our Board identifies as a member of an underserved community or as female

What are you doing to help create a more diverse employee community?

We create the conditions for our employees to thrive, facilitating their learning and growth through a richly supportive workplace setting.
Part of that is creating a speak-up culture; we have cultivated an environment where every voice is heard, and we encourage the expression of different points of view in decision-making processes. At every turn, we encourage deep listening, thoughtful consideration, and open-mindedness that allows for decisions to be changed or refined in step with new data. By embracing our team members’ differences, we create wins for our organization and for patients.

Frequently Asked Questions

What is MIMRYLO™ used for?

MIMRYLO™ is used for the treatment of erythrocytosis in adults with Polycythemia Vera.

Who developed MIMRYLO™?

MIMRYLO™ was developed by Protagonist Therapeutics.

What does FDA approval mean for MIMRYLO™?

FDA approval allows MIMRYLO™ to be marketed and prescribed for patients with Polycythemia Vera.

How does Protagonist support diversity?

Protagonist promotes diversity through various programs and initiatives, ensuring an inclusive workplace.

Last updated: Aug 31, 2026